The global colorectal cancer therapeutics market was valued at USD 9.26 billion in 2018 and is expected to grow significantly, reaching approximately USD 26.49 billion by 2032. This growth reflects a compound annual growth rate (CAGR) of 7.8% over the forecast period. In 2018, North America led the market, accounting for 44.6% of the total global share.
The colorectal cancer therapeutics market is steadily growing due to the rising incidence of colorectal cancer worldwide and continuous advancements in treatment options. This market includes various therapies such as chemotherapy, immunotherapy, and targeted treatments designed to improve patient outcomes. Increasing awareness about early diagnosis, improvements in healthcare infrastructure, and ongoing research are driving market expansion. Despite challenges like high treatment costs and side effects, the demand for effective and personalized therapies continues to fuel growth across different regions globally.
Tariff Impact Analysis For Colorectal Cancer Therapeutics Market:
Colorectal Cancer Therapeutics Market Overview:
The colorectal cancer therapeutics market is growing steadily due to the increasing number of people being diagnosed with colorectal cancer around the world. With rising awareness about early detection and better treatment options becoming available, more patients are receiving timely care. This is helping drive the demand for new and effective therapies. Advances in targeted therapies, immunotherapies, and combination treatments are also playing a big role in the market’s growth.
Market Segmentation
By Therapy Type:
Chemotherapy: Traditional treatment option for colorectal cancer.
Immunotherapy: Emerging as a preferred choice due to its efficacy in specific patient populations.
Targeted Therapy: Focuses on specific genetic mutations associated with colorectal cancer.
By Cancer Type:
Colorectal Adenocarcinoma: Most common form of colorectal cancer.
Gastrointestinal Carcinoid Tumors: Less common but significant form.
Mordor Intelligence
By Treatment Provider:
Hospitals: Primary centers for colorectal cancer treatment.
Specialty Clinics: Provide specialized care and treatment options.
Cancer Research Centers: Focus on advanced treatments and clinical trials.
List Of Key Companies Profiled:
Genentech, Inc.
Eli Lilly and Company
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Bristol Myers Squibb
Sanofi
Merck Sharp & Dohme Corp.
Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.)
Bayer AG
Regeneron Pharmaceuticals, Inc.
Novartis AG
Ipsen Biopharmaceuticals, Inc.
Market Growth
Steady Expansion: The global colorectal cancer therapeutics market is experiencing consistent growth, driven by the increasing incidence of colorectal cancer and advancements in treatment modalities.
Therapeutic Advancements: Innovations in treatment options, including chemotherapy, immunotherapy, and targeted therapies, are contributing to improved patient outcomes and expanding market opportunities.
Restraining Factors:
While the colorectal cancer therapeutics market is expanding, there are some challenges. High treatment costs and limited access to advanced therapies in low-income regions are major barriers. In some countries, late diagnosis due to poor screening programs reduces the effectiveness of treatment. In addition, side effects of certain therapies and the time it takes for new drugs to get approved can slow down market growth. Patent expirations of major drugs may also lead to increased competition from generic alternatives.
Regional Analysis:
Regionally, the colorectal cancer therapeutics market is led by North America, thanks to strong healthcare infrastructure, higher awareness, and heavy investment in research and development. Europe follows closely, supported by government initiatives and advanced treatment options. The Asia-Pacific region is showing the fastest growth due to a large population base, rising healthcare spending, and increasing cancer awareness in countries like China, India, and Japan. Meanwhile, Latin America and the Middle East & Africa are experiencing slower growth due to limited resources and healthcare access, although gradual improvements are being seen.
Key Industry Developments:
In June 2021, Bristol Myers Squibb received approval from the European Commission (EC) for the use of Opdivo in combination with Yervoy to treat adult patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). This approval grants marketing authorization across all European Union member states, as well as Norway, Iceland, and Liechtenstein.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner - Mahalunge Road,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.: +1 424 253 0390
U.K.: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com